Dianthus Therapeutics (NASDAQ:DNTH) Stock Price Down 2.4%

Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report) shares dropped 2.4% during mid-day trading on Monday . The stock traded as low as $23.70 and last traded at $23.70. Approximately 5,893 shares changed hands during mid-day trading, a decline of 96% from the average daily volume of 141,464 shares. The stock had previously closed at $24.29.

Analyst Ratings Changes

A number of research firms have commented on DNTH. Raymond James upped their target price on shares of Dianthus Therapeutics from $34.00 to $51.00 and gave the company an "outperform" rating in a research report on Thursday, April 18th. Jefferies Financial Group increased their price objective on shares of Dianthus Therapeutics from $22.00 to $39.00 and gave the stock a "buy" rating in a research report on Friday, March 22nd. Wedbush boosted their target price on Dianthus Therapeutics from $33.00 to $38.00 and gave the company an "outperform" rating in a research report on Friday. Finally, Stifel Nicolaus initiated coverage on Dianthus Therapeutics in a research report on Thursday, February 15th. They set a "buy" rating and a $44.00 price target for the company. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Dianthus Therapeutics presently has an average rating of "Buy" and a consensus price target of $43.40.

Dianthus Therapeutics Trading Up 7.1 %

The stock's fifty day simple moving average is $25.48 and its 200-day simple moving average is $18.55. The company has a market capitalization of $763.39 million, a price-to-earnings ratio of -4.46 and a beta of 1.77.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last issued its quarterly earnings results on Thursday, March 21st. The company reported ($0.71) earnings per share for the quarter, topping the consensus estimate of ($1.11) by $0.40. The company had revenue of $0.46 million for the quarter, compared to analysts' expectations of $0.73 million. On average, analysts anticipate that Dianthus Therapeutics, Inc. will post -1.92 EPS for the current fiscal year.

Institutional Investors Weigh In On Dianthus Therapeutics

A number of large investors have recently modified their holdings of the company. Atlas Venture Life Science Advisors LLC acquired a new position in shares of Dianthus Therapeutics during the third quarter worth $3,240,000. FMR LLC acquired a new position in shares of Dianthus Therapeutics during the 3rd quarter worth about $28,961,000. Citigroup Inc. purchased a new position in shares of Dianthus Therapeutics in the 3rd quarter valued at about $53,000. Acadian Asset Management LLC acquired a new stake in shares of Dianthus Therapeutics during the 3rd quarter worth about $303,000. Finally, Avidity Partners Management LP purchased a new stake in Dianthus Therapeutics during the third quarter worth approximately $16,644,000. 47.53% of the stock is owned by hedge funds and other institutional investors.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.